Seroprevalence of anti-Lassa Virus IgG antibodies in three districts of Sierra Leone: A cross-sectional, population-based study

Background Lassa virus (LASV), the cause of the acute viral hemorrhagic illness Lassa fever (LF), is endemic in West Africa. Infections in humans occur mainly after exposure to infected excrement or urine of the rodent-host, Mastomys natalensis. The prevalence of exposure to LASV in Sierra Leone is crudely estimated and largely unknown. This cross-sectional study aimed to establish a baseline point seroprevalence of IgG antibodies to LASV in three administrative districts of Sierra Leone and identify potential risk factors for seropositivity and LASV exposure. Methodology and principal findings Between 2015 and 2018, over 10,642 participants from Kenema, Tonkolili, and Port Loko Districts were enrolled in this cross-sectional study. Previous LASV and LF epidemiological studies support classification of these districts as “endemic,” “emerging,” and “non-endemic”, respectively. Dried blood spot samples were tested for LASV antibodies by ELISA to determine the seropositivity of participants, indicating previous exposure to LASV. Surveys were administered to each participant to assess demographic and environmental factors associated with a higher risk of exposure to LASV. Overall seroprevalence for antibodies to LASV was 16.0%. In Kenema, Port Loko, and Tonkolili Districts, seroprevalences were 20.1%, 14.1%, and 10.6%, respectively. In a multivariate analysis, individuals were more likely to be LASV seropositive if they were living in Kenema District, regardless of sex, age, or occupation. Environmental factors contributed to an increased risk of LASV exposure, including poor housing construction and proximity to bushland, forested areas, and refuse. Conclusions and significance In this study we determine a baseline LASV seroprevalence in three districts which will inform future epidemiological, ecological, and clinical studies on LF and the LASV in Sierra Leone. The heterogeneity of the distribution of LASV and LF over both space, and time, can make the design of efficacy trials and intervention programs difficult. Having more studies on the prevalence of LASV and identifying potential hyper-endemic areas will greatly increase the awareness of LF and improve targeted control programs related to LASV.

[1]  C. Donnelly,et al.  Geographical drivers and climate-linked dynamics of Lassa fever in Nigeria , 2021, Nature Communications.

[2]  C. Zambrana‐Torrelio,et al.  Land-use change and rodent-borne diseases: hazards on the shared socioeconomic pathways , 2021, Philosophical Transactions of the Royal Society B.

[3]  P. Wise,et al.  Health seeking behavior after the 2013–16 Ebola epidemic: Lassa fever as a metric of persistent changes in Kenema District, Sierra Leone , 2021, PLoS neglected tropical diseases.

[4]  R. Kock,et al.  The niche of One Health approaches in Lassa fever surveillance and control , 2021, Annals of Clinical Microbiology and Antimicrobials.

[5]  Donald S. Grant,et al.  Space-Time Trends in Lassa Fever in Sierra Leone by ELISA Serostatus, 2012–2019 , 2021, Microorganisms.

[6]  N. Magassouba,et al.  Hunting and consumption of rodents by children in the Lassa fever endemic area of Faranah, Guinea , 2021, PLoS neglected tropical diseases.

[7]  D. Hamer,et al.  Lassa Fever: An Evolving Emergency in West Africa. , 2020, The American journal of tropical medicine and hygiene.

[8]  Pardis C Sabeti,et al.  Acute Kidney Injury and Mortality in Pediatric Lassa fever versus Question of Access to Dialysis. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  S. Kenmoe,et al.  Systematic review and meta-analysis of the epidemiology of Lassa virus in humans, rodents and other mammals in sub-Saharan Africa , 2020, PLoS neglected tropical diseases.

[10]  Joshua C. Johnson,et al.  Natural History of Aerosol Induced Lassa Fever in Non-Human Primates , 2020, Viruses.

[11]  M. Koopmans,et al.  Public health response to two imported, epidemiologically related cases of Lassa fever in the Netherlands (ex Sierra Leone), November 2019 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[12]  E. Fichet-Calvet,et al.  Systematics, Ecology, and Host Switching: Attributes Affecting Emergence of the Lassa Virus in Rodents across Western Africa , 2020, Viruses.

[13]  C. Picard,et al.  Lassa fever in Benin: description of the 2014 and 2016 epidemics and genetic characterization of a new Lassa virus , 2020, Emerging microbes & infections.

[14]  S. Günther,et al.  Households as hotspots of Lassa fever? Assessing the spatial distribution of Lassa virus-infected rodents in rural villages of Guinea , 2020, Emerging Microbes and Infections.

[15]  C. Ihekweazu,et al.  Improving Cross-Border Preparedness and Response: Lessons Learned from 3 Lassa Fever Outbreaks Across Benin, Nigeria, and Togo, 2017-2019. , 2020, Health security.

[16]  S. Günther,et al.  Lassa Virus in Pygmy Mice, Benin, 2016–2017 , 2019, Emerging infectious diseases.

[17]  R. Peeling,et al.  Sensitivity and specificity of diagnostic tests for Lassa fever: a systematic review , 2019, BMC Infectious Diseases.

[18]  I. Fall,et al.  Investigation of a cross-border case of Lassa fever in West Africa , 2019, BMC Infectious Diseases.

[19]  E. Musa,et al.  Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1–May 6, 2018 , 2019, Emerging infectious diseases.

[20]  C. Ihekweazu,et al.  A cluster of nosocomial Lassa fever cases in a tertiary health facility in Nigeria: Description and lessons learned, 2018. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[21]  A. Akhmetzhanov,et al.  Quantifying the seasonal drivers of transmission for Lassa fever in Nigeria , 2019, Philosophical Transactions of the Royal Society B.

[22]  Donald S. Grant,et al.  A medical records and data capture and management system for Lassa fever in Sierra Leone: Approach, implementation, and challenges , 2019, PloS one.

[23]  H. Leirs,et al.  Evaluation of rodent control to fight Lassa fever based on field data and mathematical modelling , 2019, Emerging microbes & infections.

[24]  P. Jahrling,et al.  Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever , 2018, Nature Communications.

[25]  O. Ilesanmi,et al.  Lessons Learnt from Epidemiological Investigation of Lassa Fever Outbreak in a Southwest State of Nigeria December 2015 to April 2016 , 2018, PLoS currents.

[26]  A. Bråve,et al.  Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods , 2018, Emerging infectious diseases.

[27]  Oluwadamilola Abiodun-Adewusi,et al.  Knowledge of Lassa fever and use of infection prevention and control facilities among health care workers during Lassa fever outbreak in Ondo State, Nigeria , 2018, The Pan African medical journal.

[28]  Pardis C Sabeti,et al.  Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever , 2018, Scientific Reports.

[29]  H. Leirs,et al.  Movement Patterns of Small Rodents in Lassa Fever-Endemic Villages in Guinea , 2018, EcoHealth.

[30]  S. Hallam,et al.  Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development , 2018, npj Vaccines.

[31]  Kate E. Jones,et al.  Understanding the cryptic nature of Lassa fever in West Africa , 2017, Pathogens and Global Health.

[32]  Pardis C Sabeti,et al.  Prevalence of Lassa Virus Disease (LVD) in Nigerian children with fever or fever and convulsions in an endemic area , 2017, PLoS neglected tropical diseases.

[33]  P. Horby,et al.  CONSISE statement on the reporting of Seroepidemiologic Studies for influenza (ROSES‐I statement): an extension of the STROBE statement , 2016, Influenza and other respiratory viruses.

[34]  N. Wauquier,et al.  Serosurveillance of viral pathogens circulating in West Africa , 2016, Virology Journal.

[35]  S. Günther,et al.  New Hosts of The Lassa Virus , 2016, Scientific Reports.

[36]  H. Feldmann,et al.  Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali , 2016, Emerging infectious diseases.

[37]  Peter M Atkinson,et al.  Moving interdisciplinary science forward: integrating participatory modelling with mathematical modelling of zoonotic disease in Africa , 2016, Infectious Diseases of Poverty.

[38]  Elizabeth M. Ryan,et al.  Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus , 2015, Cell.

[39]  Nick Golding,et al.  Mapping the zoonotic niche of Lassa fever in Africa , 2015, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[40]  Joseph N. Fair,et al.  Undiagnosed Acute Viral Febrile Illnesses, Sierra Leone , 2014, Emerging infectious diseases.

[41]  S. Clark,et al.  Migration and the epidemiological transition: insights from the Agincourt sub-district of northeast South Africa , 2014, Global health action.

[42]  Paolo Vineis,et al.  Strengthening the Reporting of Molecular Epidemiology for Infectious Diseases (STROME-ID): an extension of the STROBE statement. , 2014, The Lancet. Infectious diseases.

[43]  Pardis C Sabeti,et al.  Lassa Fever in Post-Conflict Sierra Leone , 2014, PLoS neglected tropical diseases.

[44]  K. Ukwaja,et al.  Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012). , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[45]  P. Laurinmäki,et al.  Isolation, Identification, and Characterization of Novel Arenaviruses, the Etiological Agents of Boid Inclusion Body Disease , 2022 .

[46]  B. Haagmans,et al.  Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands. , 2013, The Journal of general virology.

[47]  L. Moses,et al.  A historical look at the first reported cases of Lassa fever: IgG antibodies 40 years after acute infection. , 2013, The American journal of tropical medicine and hygiene.

[48]  H. Feldmann,et al.  Lassa Fever in West Africa: Evidence for an Expanded Region of Endemicity , 2012, Zoonoses and public health.

[49]  Joseph L. DeRisi,et al.  Identification, Characterization, and In Vitro Culture of Highly Divergent Arenaviruses from Boa Constrictors and Annulated Tree Boas: Candidate Etiological Agents for Snake Inclusion Body Disease , 2012, mBio.

[50]  Caitlin M Worrell,et al.  Drug coverage surveys for neglected tropical diseases: 10 years of field experience. , 2012, The American journal of tropical medicine and hygiene.

[51]  D. Bausch,et al.  Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa Fever , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  Rosamund F. Lewis,et al.  Prevalence and Risk Factors of Lassa Seropositivity in Inhabitants of the Forest Region of Guinea: A Cross-Sectional Study , 2009, PLoS neglected tropical diseases.

[53]  S. Pocock,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.

[54]  W. Schmidt,et al.  Poor housing quality increases risk of rodent infestation and Lassa fever in refugee camps of Sierra Leone. , 2007, The American journal of tropical medicine and hygiene.

[55]  Alex Dmitrienko,et al.  Pharmaceutical Statistics Using SAS: A Practical Guide , 2007 .

[56]  C. Drosten,et al.  Reverse ELISA for IgG and IgM antibodies to detect Lassa virus infections in Africa. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[57]  J. McCormick,et al.  Lassa fever vaccine , 2004, Expert review of vaccines.

[58]  Debbie Baglole,et al.  Lassa fever: epidemiology, clinical features, and social consequences , 2003, BMJ : British Medical Journal.

[59]  T. Ksiazek,et al.  Lassa fever in Guinea: II. Distribution and prevalence of Lassa virus infection in small mammals. , 2001, Vector borne and zoonotic diseases.

[60]  S Greenland,et al.  Multilevel Modeling in Epidemiology with GLIMMIX , 2000, Epidemiology.

[61]  L. Hutwagner,et al.  Effective Vaccine for Lassa Fever , 2000, Journal of Virology.

[62]  Roel Bosker,et al.  Multilevel analysis : an introduction to basic and advanced multilevel modeling , 1999 .

[63]  E. S. Smith,et al.  A prospective study of the epidemiology and ecology of Lassa fever. , 1987, The Journal of infectious diseases.

[64]  J. McCormick,et al.  Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. , 1983, The American journal of tropical medicine and hygiene.

[65]  R. Henderson,et al.  Cluster sampling to assess immunization coverage: a review of experience with a simplified sampling method. , 1982, Bulletin of the World Health Organization.

[66]  A. Anusz.  [Lassa fever]. , 1981, Pielegniarka i polozna.

[67]  T. Monath.  Lassa fever: review of epidemiology and epizootiology. , 1975, Bulletin of the World Health Organization.

[68]  T. Monath,et al.  Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. , 1974, The American journal of tropical medicine and hygiene.